TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06325449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STREAM program
Description: The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
Study: NCT06258525

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard of care oxaliplatin-based chemotherapy
Description: mFOLFOX6 or CAPOX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) supplement
Description: (400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
Study: NCT04374448

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sinonasal Benign or Malignant Tumor Resection
Description: During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skull Base Surgery (Assessment of Nasoseptal Flap)
Description: In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Sinus Surgery
Description: During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior Epistaxis Management (SPA Ligation)
Description: During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
Study: NCT05910853

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: Blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: Blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: Blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: Blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: Blood donation
Study: NCT04904120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [203Pb]VMT01
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [203Pb]VMT01
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]VMT02
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]VMT02
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion
Study: NCT06414564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 780G insulin pump
Description: Subjects on insulin infusion by 780G AHCL system
Study: NCT05874271

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Revised case management package
Description: 1. Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total) (Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management
Study: NCT05234502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)
Description: In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.

Intervention type: OTHER
Group type: OTHER
Intervention: Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)
Description: In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)
Description: A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
Study: NCT04818892

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological Assay for SARS-CoV-2
Description: LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological Assay for SARS-CoV-2
Description: LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
Study: NCT05166876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar Sodium
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar Sodium
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days
Study: NCT05974501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica
Description: Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: 200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: 30mg administered via IV once postoperatively within 24 hours for pain and swelling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: 30mg administered via IV once postoperatively within 24 hours for pain and swelling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 milliliters Ropivacaine 0.2% administered via injection perioperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
Study: NCT05770674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Month vs. 12 Months DAPT
Description: Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Month vs. 12 Months DAPT
Description: Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI
Study: NCT04842032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Study: NCT05062993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal epidural pulse radio frequency
Description: A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
Study: NCT04841473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAIN Concussion Education
Description: Participants will receive the TRAIN concussion education module.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Concussion Education
Description: Participants will receive a standard concussion education module.
Study: NCT05566483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: exercise protocol
Study: NCT05608928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capscan device
Description: The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body.
Study: NCT06258525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: At 1-Month
Study: NCT05608928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capscan device
Description: The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body.
Study: NCT05820893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resistant Potato Starch
Description: MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
Study: NCT05608928

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT05166876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 MG
Description: 75 mg TID for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days
Study: NCT04507360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study 1, Generic Response
Description: Participants will be provided with the generic/current response to screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study 1, Generic Response
Description: Participants will be provided with the generic/current response to screening.
Study: NCT06118918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II comprehensive cardiac rehabilitation program
Description: the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation ...etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
Study: NCT02431221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04507360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study 1, Generic Response
Description: Participants will be provided with the generic/current response to screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study 1, Tailored Response
Description: Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes or no).
Study: NCT05703932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based exercises
Description: Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
Study: NCT06562777

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05241691

Intervention type: DEVICE
Intervention: Guided Growth Plate System Plus
Description: The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
Study: NCT05076253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin plus standard care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin plus standard care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Standard care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard care
Study: NCT05704127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent Moxibustion Robot
Description: The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial moxibustion
Description: The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
Study: NCT05378698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Application of Tralokinumab
Description: 2 Arms 20 patients 5 healthy controls
Study: NCT05997394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A prayer concert will be held for the participants.
Description: Participants who are in the experimental group will be given a prayer audience.
Study: NCT05535218

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
Description: Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant).
Study: NCT05585281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QL1101
Description: Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
Study: NCT04970953

Intervention type: PROCEDURE
Intervention: Right heart catheterization
Description: Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
Study: NCT04998136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Description: Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide 2.4 mg)
Description: Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
Study: NCT04422275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Concentration Essential Oil
Description: High-concentration essential oil will include 1 ml of essential oil per jar.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Concentration Essential Oil
Description: High-concentration essential oil will include 1 ml of essential oil per jar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
Study: NCT06124703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Description: Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba Extract
Description: Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.